All In Biotech

NDA 202497 · Acrotech

Marqibo Kit

Vincristine Sulfate · Intravenous

Accelerated approvalOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Mar 15, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Aug 9, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,362

387 Phase 3, 178 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 9, 2012 Original approval · Type 5 - New Formulation or New Manufacturer Accelerated approvalOrphanReviewSummary ReviewLabel
1 products under this application
  • MARQIBO KIT · VINCRISTINE SULFATE 5MG/5ML (1MG/ML) · INJECTABLE, LIPOSOMAL, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Vincristine" as an intervention, any sponsor and status, largest first.

All 1,362 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,492 on PubMed

Sponsor: Acrotech

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.